Europe's Take On Excessive Pricing: Recent Enforcement Practice in Italy and the UK
12 PM EDT
Last year saw antitrust investigations into allegations of abusive “excessive pricing” in Italy, the UK and elsewhere. In November 2016, the Italian authority fined Aspen Holdings USD 6m for allegedly increasing the price of cancer drugs by up to 1,500% and in December 2016, the UK fined Pfizer and its distributor over USD 110m for an alleged 2,600% price increase for an epilepsy drug. On 3 May 2017, the European consumer body asked Competition Commissioner Vestager whether the pricing practices of some pharmaceutical companies constituted an abusive of a dominant position. This panel of UK/Italian enforcers describes recent enforcement practice, and when antitrust should intervene.
FREE: Antitrust Section Members, Government, Non-profit Employees, Students. $25 Other Non-Members
Explore Section benefits or call 1-800-285-2221 to join. Code RAT14IP25. For this and all upcoming events visit http://ambar.org/atevents.
CLE: The ABA is not seeking CLE credit for this program.
Audio Archive: Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.